Abbott settles appeal over $495 million infant formula verdict

Abbott Laboratories has reached a settlement to resolve its appeal of a $495 million verdict tied to its specialized infant formula for premature babies. The company reached the deal to end the litigation, but details were not immediately available in court documents filed Monday in Missouri’s appeals court. Abbott and the plaintiff’s attorneys did not respond right away to questions. In 2024, a St. Louis jury found Abbott’s formula caused a girl in Illinois to develop necrotizing enterocolitis (NEC), a serious bowel disease. Abbott had been appealing after state appellate rulings.